CASE REPORT
Extramedullary myeloid cell tumours localised to the mediastinum. A rare clinicopathological entity with unique karyotypic features

R Nounou, H Al-Zahrani H, D S Ajarim, J Martin, A Iqbal, R Naufal, R Stuart, G Roberts, M Gyger

Extramedullary myeloid cell tumour (EMMT) localised to the mediastinum is a rare manifestation of acute myeloid leukaemia, forming less than 4% of all cases of EMMT. In contrast to other types of EMMT, cytogenetic characteristics of this rare entity are relatively unknown. This report describes a patient with EMMT who had evidence of superior vena cava syndrome and bilateral pleural effusions. Small lymph nodes were palpable in both axillae. The white blood cell count (WBC) was 8 \times 10^9/litre with a normal differential count, haemoglobin (Hb) was 145 g/litre, and platelets were 327 \times 10^9/litre. Computerised tomography (CT) of the chest showed a mediastinal mass with areas of necrosis causing compression of the trachea, oesophagus, and superior vena cava (fig 1A, B). An anterior mediastinal core biopsy was interpreted as crushed material with sheets of malignant appearing lymphocytes with irregularly shaped nuclei, consistent with large B cell lymphoma. The patient refused a bone marrow aspirate and biopsy procedure. On the basis of the histology report, the patient was treated with a first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).

When first seen at our institution on 31 July 2000 for completion of treatment, the patient was asymptomatic. Physical examination was unremarkable. CXR and CT showed a reduction in the size of the mediastinal mass and persistent pleural effusions (fig 1C). Initial biopsy material could not be adequately interpreted. Complete blood counts revealed: WBC, 7.2 \times 10^9/litre, with 5% myelocytes and 4% metamyelocytes; Hb, 124 g/litre; and platelets, 325 \times 10^9/litre and scattered circulating malignant cells, which prompted a bone marrow examination, pleural fluid analysis, and biopsy of the residual mediastinal mass.

Malignant myeloid precursor cells can find a niche to proliferate outside their normal bone marrow habitat in almost all tissues of the body, an unusual feature initially reported almost two centuries ago. When they do so, they most often invade the periosteum and bone, soft tissues, skin, and lymph nodes. Characteristically, they form tumorous aggregates or masses initially described as granulocytic sarcomas, and later referred to as extramedullary myeloid tumours (EMMTs). They can present before, at the same time, or after a diagnosis of the acute myeloid process. Awareness in recent years of the probability of misdiagnosing EMMTs when they present as an isolated process has been of no avail. Indeed, in a recent retrospective study, all cases presenting without a previous history of myeloproliferative disorder had an initial incorrect diagnosis, mostly of lymphoma.

In the past decade, information gained from cytogenetic studies has contributed to identifying specific subsets of EMMT. Comprehensive information provided by a new case studied at our institution, and from a literature review, suggests that mediastinal EMMT probably constitutes a distinct clinicopathological entity among EMMTs, with unique karyotypic features.

CASE REPORT
A 17 year old girl presented to her local hospital on 4 July 2000, with shortness of breath and dysphagia. Chest x ray (CXR) revealed bilateral pleural effusions with a large mediastinal mass. Physical examination revealed typical features of superior vena cava syndrome and bilateral pleural effusions. Small lymph nodes were palpable in both axillae. The white blood cell count (WBC) was 8 \times 10^9/litre with a normal differential count, haemoglobin (Hb) was 145 g/litre, and platelets were 327 \times 10^9/litre. Computerised tomography (CT) of the chest showed a mediastinal mass with areas of necrosis causing compression of the trachea, oesophagus, and superior vena cava (fig 1A, B). An anterior mediastinal core biopsy was interpreted as crushed material with sheets of malignant appearing lymphocytes with irregularly shaped nuclei, consistent with large B cell lymphoma. The patient refused a bone marrow aspirate and biopsy procedure. On the basis of the histology report, the patient was treated with a first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).

When first seen at our institution on 31 July 2000 for completion of treatment, the patient was asymptomatic. Physical examination was unremarkable. CXR and CT showed a reduction in the size of the mediastinal mass and persistent pleural effusions (fig 1C). Initial biopsy material could not be adequately interpreted. Complete blood counts revealed: WBC, 7.2 \times 10^9/litre, with 5% myelocytes and 4% metamyelocytes; Hb, 124 g/litre; and platelets, 325 \times 10^9/litre and scattered circulating malignant cells, which prompted a bone marrow examination, pleural fluid analysis, and biopsy of the residual mediastinal mass.

MATERIALS AND METHODS
Classification of acute myeloid leukaemia was based on standard FAB cooperative group criteria. Immunophenotypic studies were performed by multiparameter flow cytometry (FACS Caliber flow cytometer, Becton Dickinson, San Jose, California, USA). Flow cytometry was performed on the blast cells from the peripheral blood, bone marrow, pleural fluid, and mediastinal lymph node, gated on their abnormal light scatter characteristics using monoclonal antibodies (Becton Dickinson, Immunotech, Marseille, France) to myeloid, T cell, B cell, natural killer cell, and megakaryocytic antigens, in addition to HLA-DR, terminal deoxynucleotidyl transferase, and cytoplasmic myeloperoxidase. Several panels containing two or three conjugated antibodies each were used for immunophenotyping analyses: a membrane or cytoplasmic marker was considered positive when expressed by more than 20% of

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CT, computed tomography; CXR, chest x ray; EMMT, extramedullary myeloid cell tumour; Hb, haemoglobin; WBC, white blood cell count
the blast cells. Immunohistochemical stains were performed on the trephine biopsy for CD45, CD3, CD20, and CD34 antigens, and myeloperoxidase. Cytochemical staining for myeloperoxidase, Sudan black B, combined esterases, periodic acid Schiff, and acid phosphatase was performed on the bone marrow aspirate specimen. Cytogenetic analysis using standard methods was performed on cells obtained from the bone marrow aspirate. Sections (3 µm thick) from the mediastinal biopsy specimen were stained with haematoxylin and eosin, in addition to immunohistochemical staining for CD45, CD20, CD3, CD34, and myeloperoxidase.

RESULTS
Morphology and immunophenotyping
Peripheral blood, bone marrow (fig 2A,B), and pleural fluid (fig 3A) revealed the presence of large blasts with a relatively low nuclear–cytoplasmic ratio, open chromatin pattern, few prominent nucleoli, many cytoplasmic granules, and some cytoplasmic vacuolisation. Many showed cleft and convoluted nuclei. No Auer rods were seen. Flow cytometry showed that the blasts had a very high forward and side scatter, in keeping with their large size and granular cytoplasm (fig 3B). They were positive for CD45, myeloperoxidase, HLA-DR, CD4, CD15, CD11c (partial), CD64, CDw65, CD56, CD23, and CD9, and negative for CD34, CD33, and CD117. CD13 was very weakly expressed. Immunohistochemistry showed strong positivity for CD45 whereas CD34, CD20, and CD3 were negative. Cytochemistry revealed strong positivity with myeloperoxidase, Sudan black B, and chloracetate esterase, and negativity for periodic acid Schiff, acid phosphatase, and α-naphthyl acetate esterase, consistent with myeloid leukaemia.

Histology
Review of the initial lymph node biopsy showed extensive crush artifact, which precluded a definitive interpretation (fig 4A). Despite poor cellular preservation, all cells were strongly positive for myeloperoxidase, excluding the B cell nature of the infiltration and confirming a diagnosis of primary EMMT (fig 4B). The subsequent biopsy also showed localised crush artifact but cell preservation was much better. The malignant infiltrate consisted of intermediate sized cells. Nuclei were relatively round and contained a single nucleolus. Cytoplasm was moderate in amount and focally granular. Auer rods were not seen (fig 5A). Immunohistochemistry showed positivity for CD45 and myeloperoxidase. All of the other antibodies, including CD34, were negative (fig 5B).
Cyto genetics
Based on the 15 metaphases analysed, two composite karyotypes were found: one with a near triploid chromosome count (72–76 chromosomes) in 12 metaphases, and the other with a near tetraploid count (81–87 chromosomes) in three metaphases. The composite karyotypes were: 72–76, {3n}, XX, −X, +1, ?inv(1)(p32q25)x2, +5, del(5)(q13q33), +6, +7, del(7)(q22)x2, −9, −11, −14, del(17)(p11.2), +19, +19, add(19)(q13.1)x2, +20, −21, +mar1, +mar2(cp12), and 81–87, {4n}, XX, −X, −X, ?inv(1)(p32q25)x2, −2, −4, del(5)(q13q33), del(7)(q22)x2, −9, −9, −10, −11, −11, −13, −14, −14, −15, −16, −17, del(17)(p11.1), +19, +19, add(19)(q13.1)x2, +20, −21, −21, −22, +12mar(cp3). Non-random chromosome rearrangements were found in both composite karyotypes, such as inv(1)(p32q25), del(5)(q14q33), del(7)(q22), and del(17)(p11.1). The tetraploid cells also had numerous marker chromosomes. A representative karyotype is shown in fig 6.

DISCUSSION
Extramedullary myeloid tumours have been reported in almost every site in the body. However, involvement of the mediastinum is extremely rare.15 In 1988, Liu et al reported a case of mediastinal EMMT presenting with superior vena cava syndrome and reviewed 11 previously published cases.12 They showed that EMMT of the mediastinum could precede bone marrow and blood manifestations by many months, and that superior vena cava syndrome could represent the initial mode of presentation in several cases.12 In addition, as is typical of many other primary EMMTs, many of these were misdiagnosed as non-Hodgkin’s lymphoma, leading to inappropriate treatment. Cytogenetic characteristics were not reported. Since then, Tallman et al showed that a subset of EMMTs with preferential involvement of the brain, orbit, and epidural space is strongly associated with the t(8;21) translocation.8 Of 40 reported cases, only one with t(8;21) was localised to the mediastinum.13 It was reported subsequently that most EMMTs are associated with three specific karyotypic abnormalities, namely: t(8;21), inv(16), and, t(9;11).5 Since the review of Liu et al,15 nine new cases of EMMT involving the mediastinum including the present one, have been reported with karyotypic data (summarised in table 1).16–20 Interestingly, a near triploid/tetraploid karyotype was documented in five of nine cases. Au et al reported three such cases, all in women.21 Bone marrow examination revealed the presence of large blasts with bizarre and folded nuclei, as reported in our case. Structural chromosomal abnormalities

Figure 3  (A) Pleural fluid [Wright-Giemsa stain; original magnification, ×400] showing [B] involvement by the same type of blast cells with high forward and side light scatter.

Figure 4  (A) Initial biopsy specimen showing extensive crush artifact. Cell detail is absent and represented by streams of chromatin like material [haematoxylin and eosin stain; original magnification, ×400]. (B) Anti-myeloperoxidase stain [original magnification, ×400] showing widespread positivity, confirming a diagnosis of extramedullary myeloid tumour.
Figure 5  Second biopsy specimen (haematoxylin and eosin stain; original magnification, ×400) showing (A) sheets of intermediate sized blast like cells, with moderate cytoplasm and focal granularity. (B) Malignant cells are strongly positive for anti-myeloperoxidase.

Figure 6  Representative bone marrow karyotype: 75, [3n], XX, −X, +1, Finv(1)[p32q25]:=2, +5, del(5)q13q33,:6, +7, del(7)q22:=2, −9, −11, −14, del(17)[p11.2], +19, +19, add(19)[q13.1], +20, −21, +mar1, +mar2. The arrows point to abnormal chromosomes.

Table 1  Summary of the 10 cases of extramedullary myeloid tumours involving the mediastinum that have reported karyotypic data

<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>Blast cells in PB</th>
<th>Bone marrow</th>
<th>FAB</th>
<th>Immunophenotype</th>
<th>Pleural involvement</th>
<th>Karyotype</th>
<th>Remission</th>
<th>Outcome</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21/M</td>
<td>Yes</td>
<td>M₂</td>
<td>N/D</td>
<td>M₃</td>
<td>No</td>
<td>Tetraploidy</td>
<td>Yes</td>
<td>Death, relapse</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>45/F</td>
<td>Yes</td>
<td>M₁</td>
<td>CD7/13/33; HLA-DR⁺</td>
<td>No</td>
<td>Del(15)[q13q15]</td>
<td>Yes</td>
<td>Death, relapse</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>34/M</td>
<td>No</td>
<td>M₁/M₂</td>
<td>CD33⁺; HLA-DR⁺</td>
<td>Yes</td>
<td>[9;11][p22;q23]</td>
<td>Yes</td>
<td>Remission 18 months</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>29/F</td>
<td>No</td>
<td>M₂</td>
<td>CD34/33⁺; CD13⁻</td>
<td>No</td>
<td>Diploid/near tetraploid</td>
<td>No</td>
<td>Refractory death post allotransplant</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>46/F</td>
<td>Yes</td>
<td>M₄</td>
<td>CD34/7/33⁺; CD13⁻</td>
<td>No</td>
<td>Diploid/near tetraploid</td>
<td>Yes</td>
<td>Death, relapse</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>29/F</td>
<td>Yes</td>
<td>M₁</td>
<td>N/A</td>
<td>M₁</td>
<td>No</td>
<td>Near tetraploid</td>
<td>Yes</td>
<td>Death, relapse</td>
<td>17</td>
</tr>
<tr>
<td>7</td>
<td>34/F</td>
<td>No</td>
<td>M₂</td>
<td>CD33⁺; HLA-DR⁺</td>
<td>Yes</td>
<td>10, 11</td>
<td>No</td>
<td>Death, refractory disease</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>42/F</td>
<td>No</td>
<td>M₃</td>
<td>CD7/34/33⁺; CD13⁻</td>
<td>No</td>
<td>15, +19, +20</td>
<td>Yes</td>
<td>Death, heart failure</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>26/M</td>
<td>No</td>
<td>RAEB</td>
<td>CD33⁺</td>
<td>Yes</td>
<td>Normal</td>
<td>N/A</td>
<td>Death, post chemo</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>17/F</td>
<td>No</td>
<td>N/D M₁</td>
<td>CD7/65/CD56⁺; HLA-DR⁺; CD13/33⁻</td>
<td>Yes</td>
<td>Near tetraploid</td>
<td>No</td>
<td>Death</td>
<td>This paper</td>
<td></td>
</tr>
</tbody>
</table>
A near tetraploid or triploid karyotype is found in most reported cases of mediastinal extramedullary myeloid cell tumour (EMMT) and may represent a specific subset of EMMT. Because of the poor prognosis conferred by this karyotype in mediastinal EMMT, early diagnosis and integration of allogeneic stem cell transplantation as part of the therapeutic regimen might improve the clinical outcome.

**Take home messages**

- A near tetraploid or triploid karyotype is found in most reported cases of mediastinal extramedullary myeloid cell tumour (EMMT) and may represent a specific subset of EMMT.
- Because of the poor prognosis conferred by this karyotype in mediastinal EMMT, early diagnosis and integration of allogeneic stem cell transplantation as part of the therapeutic regimen might improve the clinical outcome.

**REFERENCES**

Extramedullary myeloid cell tumours localised to the mediastinum. A rare clinicopathological entity with unique karyotypic features

R Nounou, H Al-Zahrani H, D S Ajarim, J Martin, A Iqbal, R Naufal, R Stuart, G Roberts and M Gyger

*J Clin Pathol* 2002 55: 221-225

doi:

Updated information and services can be found at:
[http://jcp.bmj.com/content/55/3/221](http://jcp.bmj.com/content/55/3/221)

These include:

**References**

This article cites 24 articles, 5 of which you can access for free at:
[http://jcp.bmj.com/content/55/3/221#BIBL](http://jcp.bmj.com/content/55/3/221#BIBL)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Clinical diagnostic tests (805)
- Immunology (including allergy) (1664)

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)